中国经济网北京7月29日讯东亚药业（605177）(605177.SH)昨晚发布2025年半年度业绩预告。经财务部 门初步测算，公司预计2025年半年度实现归属于上市公司股东的净利润为-2,800万元到-3,500万元，与 上年同期(法定披露数据)相比，将出现亏损。预计2025年半年度实现归属于上市公司股东的扣除非经常 性损益的净利润为-3,300万元到-4,000万元。上年同期归属于上市公司股东的净利润为3,247.30万元。归 属于上市公司股东的扣除非经常性损益的净利润为2,693.32万元。 东亚药业2024年年度报告显示，公司的实际控制人为池正明和池骋父子。池正明直接持有公司股份 4,711.6769万股，占公司41.06%的股份；池骋直接持有公司股份778.6875万股，占公司6.79%的股份，同 时持有公司股东瑞康投资33.5295%的份额，并担任其执行事务合伙人，直接和间接合计控制8.97%的表 决权份额。池骋担任公司的董事长兼总经理，父子二人能对公司的股东大会决策产生重大影响，为公司 的实际控制人。池正明，中国国籍，已取得其他国家或地区居留权。 2024年，公司实现营业收入11.98亿元，同比 ...

Core Viewpoint - Zhejiang Dongya Pharmaceutical Co., Ltd. is expected to report a significant loss for the first half of 2025, with net profit projected to be between -28 million and -35 million yuan, indicating a decline compared to the same period last year [2][4]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to June 30, 2025 [3]. - The company anticipates a net profit attributable to shareholders of -28 million to -35 million yuan, which represents a loss compared to the previous year's profit of 32.47 million yuan [4][7]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -33 million and -40 million yuan [5]. Group 2: Reasons for Performance Decline - The primary reason for the expected loss is attributed to a decrease in gross profit by approximately 30 million yuan due to changes in product demand influenced by global economic slowdown, industry policies, and intensified competition [10]. - The company plans to recognize an inventory impairment provision of around 30 million yuan, as the net realizable value of certain inventories is expected to be lower than their cost [11]. - Despite the challenges, the company has achieved a significant milestone by obtaining its first formulation approval, which is expected to enhance its product line and competitiveness [9].

Group 1 - The company expects a net profit loss of between 28 million to 35 million yuan for the first half of 2025, with a non-recurring net profit loss of 33 million to 40 million yuan, indicating a year-on-year decline [1] - The main reasons for the profit decline are attributed to changes in product demand due to global economic slowdown, industry policies, and increased competition, leading to a decrease in gross profit of approximately 30 million yuan [1] - The company plans to make a provision for impairment of inventory assets amounting to around 30 million yuan based on prudence [1] Group 2 - The company is actively pursuing an integrated strategy for raw materials and formulations to address challenges in the pharmaceutical industry [2] - In 2023, the company raised nearly 700 million yuan through convertible bonds, investing 350 million yuan in the construction of formulation factory capacity [2] - The company has received acceptance for eight formulation product applications by the end of 2024, with the first formulation product, levofloxacin, approved in June [2] Group 3 - The company's subsidiary, Hangzhou Shanli Biopharmaceutical Technology Co., Ltd., has received the CNAS laboratory accreditation certificate, enhancing its product quality assurance and R&D capabilities [3] - The CNAS accreditation signifies the laboratory's compliance with national standards, which may facilitate international product testing and enhance global market competitiveness [3]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-039 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次业绩预告适用情形：净利润为负值。 （二）业绩预告情况 经财务部门初步测算，公司预计 2025 年半年度实现归属于上市公司股东的 净利润为-2,800 万元到-3,500 万元，与上年同期（法定披露数据）相比，将出现 亏损。 预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益的净利润 为-3,300 万元到-4,000 万元。 浙江东亚药业股份有限公司（以下简称"公司"）预计 2025 年半年度实现 归属于上市公司股东的净利润为-2,800 万元到-3,500 万元，与上年同期（法定披 露数据）相比，将出现亏损，预计 2025 年半年度实现归属于上市公司股东的扣 除非经常性损益的净利润为-3,300 万元到-4 ...

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-038 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于全资子公司获得中国合格评定国家认可委员会（CNAS） 实验室认可证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江东亚药业股份有限公司（以下简称"公司"）全资子公司杭州善礼生物 医药科技有限公司（以下简称"杭州善礼"）于近日收到中国合格评定国家认可 委 员 会 （ 英 文 名 称 为 " China National Accreditation Service for Conformity Assessment"，以下简称"CNAS"）授予的实验室认可证书，现将相关事宜公 告如下： 一、证书内容 获得机构名称：杭州善礼生物医药科技有限公司 检验检测中心注册号：CNAS L23199 生效日期：2025 年 5 月 20 日 证书主要内容：杭州善礼生物医药科技有限公司分析实验室符合 ISO/IEC 1 ...

Core Viewpoint - East Asia Pharmaceutical (605177) announced that its wholly-owned subsidiary, Hangzhou Shanli Biomedical Technology Co., Ltd., has recently obtained the laboratory accreditation certificate from the China National Accreditation Service for Conformity Assessment, which enhances the company's credibility and competitive edge in the market [1] Group 1 - The accreditation certificate is effective from May 20, 2025, to May 19, 2031, indicating a long-term recognition of the laboratory's management and technical capabilities [1] - This recognition allows Hangzhou Shanli's analysis laboratory to conduct testing according to national standards, thereby improving product quality and research capabilities [1] - The accreditation is expected to enhance customer trust and contribute to the company's high-quality development, although it will not have a significant impact on the company's current performance [1]

| 证券代码：605177 | 证券简称：东亚药业 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：111015 | 债券简称：东亚转债 | | 浙江东亚药业股份有限公司 关于可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 6 月 30 日，累计已有人民币 23,774,000 元 "东亚转债"转为公司 A 股普通股，累计转股股数为 1,153,776 股，占"东亚转 债"转股前公司已发行普通股股份总额的 1.0156%。 未转股可转债情况：截至 2025 年 6 月 30 日，尚未转股的"东亚转债" 金额为人民币 666,226,000 元，占"东亚转债"发行总量的比例为 96.5545%。 本季度转股情况：2025 年 4 月 1 日至 2025 年 6 月 30 日，"东亚转债" 未发生转股情况。 一、"东亚转债"发行上市概况 经中国证券监督管理委员会证监许可〔2023〕1165 号文核准，浙江东亚药 ...

上海君澜律师事务所 关于 浙江东亚药业股份有限公司 回购注销部分限制性股票 之 法律意见书 二〇二五年六月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于浙江东亚药业股份有限公司 回购注销部分限制性股票之 法律意见书 致：浙江东亚药业股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江东亚药业股份有限公司（以 下简称"公司"或"东亚药业"）的委托，根据《上市公司股权激励管理办法》（以 下简称"《管理办法》"）、《浙江东亚药业股份有限公司 2024 年限制性股票激励计 划》（以下简称"《激励计划》"或"本次激励计划"）的规定，就东亚药业回购注 销本次激励计划 1 名激励对象已获授但尚未解除限售的限制性股票（以下简称"本次 回购注销"）相关事项出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实 信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整， ...

Core Viewpoint - The company announced the repurchase and cancellation of 14,000 restricted stocks due to one incentive object resigning, with a repurchase price of 9.47 yuan per share [1][6][10]. Summary by Sections Announcement Details - The company’s board approved the repurchase of restricted stocks at a meeting held on June 30, 2025, following the resignation of one incentive object [1][2]. - The total number of restricted stocks to be repurchased is 14,000 shares, which represents 0.01% of the total share capital of 114,739,776 shares as of June 29, 2025 [6][7]. Repurchase Price and Funding - The repurchase price for the restricted stocks is set at 9.47 yuan per share, totaling 132,580 yuan, which will be funded entirely from the company’s own funds [6][7]. Impact on Share Capital Structure - After the repurchase and cancellation, the company’s total share capital will decrease from 114,739,776 shares to 114,725,776 shares [7][9]. - The number of restricted shares will decrease from 2,156,103 to 2,142,103 shares, while the number of unrestricted shares remains unchanged at 112,583,673 [8]. Compliance and Approval - The repurchase has been authorized by the company’s third extraordinary general meeting in 2024, and no further shareholder approval is required [6][9]. - The supervisory board has confirmed that the repurchase complies with relevant regulations and will not adversely affect the company’s financial status or operational results [9][10].

Key Points - The company announced the interest payment schedule for its convertible bonds, "东亚转债," which will begin on July 7, 2025 [1][2] - The total amount raised from the issuance of the convertible bonds is RMB 690 million, with a maturity period of 6 years and a tiered interest rate structure [1][2] - The bond's interest rates are set at 0.20% for the first year, increasing to 2.50% by the sixth year [1][2] - The bond's conversion price was adjusted from RMB 24.95 to RMB 20.60, and subsequently to RMB 20.28 due to profit distribution [2] - The interest payment for the second year will be calculated based on a rate of 0.40%, resulting in a payment of RMB 0.40 per bond before tax [4][5] - The bondholders will receive their interest payments through the China Securities Depository and Clearing Corporation Limited, and tax obligations will be handled by the payment institutions [4][5] - Non-resident enterprises holding the bonds are exempt from corporate income tax on the interest income until December 31, 2025 [5]